Phase II Study of 5-Azacytidine (Azacytidine; Vidaza) in Chronic Lymphocytic Leukemia.

Trial Profile

Phase II Study of 5-Azacytidine (Azacytidine; Vidaza) in Chronic Lymphocytic Leukemia.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 02 Jul 2015

At a glance

  • Drugs Azacitidine (Primary)
  • Indications B cell prolymphocytic leukaemia; Chronic lymphocytic leukaemia; T cell prolymphocytic leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 29 Jun 2015 Status changed from completed to discontinued as per ClinicalTrials.gov record.
    • 20 Nov 2014 Status changed from active, no longer recruiting to discontinued as reported by M.D. Anderson Cancer Center record.
    • 18 Nov 2014 According to the ClinicalTrials.gov record, status changed from discontinued to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top